glp 1 drugs pregnancy Accidental early‑pregnancy use of GLP‑1 shows no major safety signal, study finds How GLP-1 Drugs Can Affect

These effects were mostly accompanied by decreased maternal food consumption and reduced maternal weight

The phase 3 OASIS 1 trial investigated high dose oral semaglutide in participants with overweight or obesity, but without T2D (58)

Table 1 List of Clinical Trials Evaluating the Cardiovascular Efficacy and Safety of GLP-1 RAs GLP-1 RA, glucagon-like peptide-1 receptor agonist

All reported rates, rate differences, cumulative incidences, and hazard ratios were adjusted using propensity score weighting

Multi-indication label expansion: Semaglutide approved across obesity, cardiovascular risk reduction, MASH, and sleep apnea creates a total addressable patient population of approximately 640 million globally nearly four times the obesity-only base adding new prescriber populations including cardiologists, hepatologists, and sleep medicine specialists

Kelly SH, Wu Y, Varadhan AK, Curvino EJ, Chong AS, Collier JH